Rajeev Ayyagari
 
                    Education
Ph.D., biostatistics, Harvard University; M.S., computer science, University of Maryland; M.A. and B.A., statistics, Indian Statistical Institute
Summary of Experience
Dr. Ayyagari is experienced in applying statistical techniques to the study of clinical and economic outcomes in a broad range of disease areas, including diabetes, cardiovascular disease, oncology, psychiatry, immunology, and infectious diseases. His expertise includes comparative efficacy and safety, risk prediction, missing data problems, identification of causal effects in observational studies, robust estimation, indirect and mixed treatment comparisons, and applications of artificial intelligence (AI) and large language models to health care. Dr. Ayyagari’s recent work includes evaluating the comparative efficacy of inhibitors in diabetes for regulatory submissions, assessing the causal effect of adherence on diabetes outcomes, developing stroke risk models incorporating pulse pressure, developing a social experiment on attitudes towards people with movement disorders, leading the development of software tools to communicate the economic value of therapies, and leading the deployment of generative AI-based systems for automated literature summarization. His research has been published in the Journal of the American Statistical Association, Journal of the National Cancer Institute, Cancer Treatment Reviews, Pediatric Pulmonology, and elsewhere. Dr. Ayyagari has also presented his work at health care and data mining conferences. Prior to joining Analysis Group, he was a research fellow at the Harvard School of Public Health and a biostatistician with Information Management Services, Inc.
- 
                                                        Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the USBMC Cancer, 2024 
 2024Whitman ED, Totev TI, Jiang S, da Costa WL Jr, Grebennik D, Wang H, Boca AE, Ayyagari R 
- 
                                                        Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesClinical and Translational Gastroenterology, 2024 
 2024Lembo A, Cash BD, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M 
- 
                                                        Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United StatesJournal of Clinical Psychiatry, 2023 
 2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S 
- 
                                                        Safety Differences across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate CancerFuture Oncology, 2023 
 2023Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR 
- 
                                                        Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populationsClinical Kidney Journal, 2023 
 2023Sackeyfio A, Lopes RD, Kovesdy CP, Cases A, Mallett SA, Ballew N, Keeley TJ, Garcia-Horton V, Ayyagari R, Camejo RR, Johansen KL, Sutton AJ, Dasgupta I 
- 
                                                        Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United StatesJournal of Patient-reported Outcomes, 2023 
 2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S 
- 
                                                        Health-care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesisNeurogastroenterology & Motility, 2022 
 2022Chen YJ, Tang W, Ionescu-Ittu R, Ayyagari R, Wu E, Huh SY, Parkman HP 
- 
                                                        The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect ComparisonAdvances in Therapy, 2022 
 2022Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR 
- 
                                                        Long-term burden of respiratory complications associated with extreme prematurity: An analysis of US Medicaid claimsPediatrics & Neonatology, 2022 
 2022Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP, Siffel C 
- 
                                                        Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraineThe Journal of Headache and Pain, 2022 
 2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R 
- 
                                                        Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion CancersCancers (Basel), 2022 
 2022Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U 
- 
                                                        Defining Utility Values for Chorea Health States in Patients with Huntington's DiseaseAdvances in Therapy, 2022 
 2022Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R 
- 
                                                        Defining utility values for patients with tardive dyskinesiaCurrent Medical Research and Opinion, 2022 
 2022Ayyagari R, Goldschmidt D, Zhou M, Ribalov R, Caroff SN, Leo S 
- 
                                                        Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database AnalysisNeurology and Therapy, 2022 
 2022Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S 
- 
                                                        Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart studyThe Journal of Headache and Pain, 2022 
 2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R 
- 
                                                        Burden of Comorbidities and Healthcare Resource Utilization among Medicaid-Enrolled Extremely Premature InfantsJournal of Health Economics and Outcomes Research, 2022 
 2022Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP 
- 
                                                        Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USACNS Drugs, 2021 
 2021Farahbakhshian S, Ayyagari R, Barczak DS, Gill SK, Tang W, Kulalert T, Jenkins M, Spalding W 
- 
                                                        Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate CancerThe Journal of Urology, 2021 
 2021Halabi S, Jiang S, Terasawa E, García-Horton V, Ayyagari R, Waldeck AR, Shore N 
- 
                                                        The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral ImmunotherapyAdvances in Therapy, 2021 
 2021Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S 
- 
                                                        The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with SchizophreniaClinical Drug Investigation, 2021 
 2021Zichlin ML, Mu F, Leo S, Ayyagari R 
- 
                                                        Indirect Comparison of Darolutamide Versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate CancerJournal of Urology, 2021 
 2021Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N 
- 
                                                        Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational StudyDiabetes Therapy, 2020 
 2020Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood EG, Hollander P, Fonseca V 
- 
                                                        Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesiaBMC Psychiatry, 2020 
 2020Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B 
- 
                                                        Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disordersJournal of Medical Economics, 2020 
 2020Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B 
- 
                                                        Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasiaExpert Review of Pharmacoeconomics & Outcomes Research, 2020 
 2020Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP 
- 
                                                        Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysisJournal of Comparative Effectiveness Research, 2020 
 2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J 
- 
                                                        Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndromeTherapeutic Advances in Gastroenterology, January 1, 2019 
 2019Lacy B, Ayyagari R, Guérin A, Lopez A, Shi S, Luo M 
- 
                                                        Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancerBreast Journal, 2019 
 2019Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA 
- 
                                                        
- 
                                                        Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm InfantsFrontiers in Pediatrics, 2019 
 2019Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP 
- 
                                                        The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disordersCurrent Medical Research and Opinion, 2019 
 2019McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B 
- 
                                                        Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia AJournal of Blood Medicine, 2019 
 2019Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R 
- 
                                                        Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity IndexActa Dermato-Venereologica, 2019 
 2019Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L 
- 
                                                        Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysisClinical Therapeutics. Apr 2018;40(4):628-639 e623 
 2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA 
- 
                                                        A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatmentThe Journal of Clinical Hypertension. 2018 Jun;20(6):1058-1066 
 2018Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S 
- 
                                                        Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysisCurrent Medical Research and Opinion. 2018 Sep;34(9):1645-1652 
 2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA 
- 
                                                        Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Advances in Therapy. Dec 2017;34(12):2566-2584 
 2017Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA 
- 
                                                        A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UKEur J Health Econ. Jan 2018;19(1):21-35 
 2017Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA 
- 
                                                        Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumorsAmerican Health and Drug Benefits. November 2017;10(8):408-415 
 2017Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB 
- 
                                                        Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparisonEuropean Child and Adolescent Psychiatry. Aug 2017;26(8):875-897 
 2017Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V 
- 
                                                        Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentDiabetes Therapy, 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4 
 2016Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH 
- 
                                                        Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia AJournal of Blood Medicine, 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23 
 2016Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J 
- 
                                                        Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-AnalysisCurr Med Res Opin. 2015 May 7:1-48 
 2015Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D 
- 
                                                        A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended carePediatr Pulmonol. 2013 Oct;48(10):954-61 
 2012Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L 
- 
                                                        May 5, 2024
- 
                                                        November 17, 2024
 
        